Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Vylor Inc. · VYLR · FY2026 Q3 · Calendar Q4 2026
The supplied call analysis points to a business transitioning toward more licensing income, price-and-mix gains, and productivity savings. Reaffirmed guidance and the product pipeline support management's growth case, while weather, farmer financing conditions, regulatory timing, and licensing execution remain meaningful uncertainties.
Research this report with FN2. Free to start; review your question before sending.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Management said the Corteva separation was completed on time and under budget, and described moving Brazil soybeans to a licensing-only model. The call analysis also identifies net royalty-neutral status and a planned 2027 hybrid wheat launch as notable developments.
Management maintained FY2026 guidance, including approximately 3% revenue growth to $10.4 billion and approximately 10% EBITDA growth to $2.8 billion, with margin expansion. The analysis also reports a 7–8% annual EBITDA growth expectation through 2029.
Follow VYLR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeLatest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Upside is calculated against the persisted current price $68.09. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BNP Paribas | Analyst unavailable | $75 | $76.96 | +10.1% | Oct 14, 2026 |
| Deutsche Bank | David Begleiter | $90 | $76.96 | +32.2% | Oct 14, 2026 |
| UBS | Lucas Beaumont | $89 | $73.15 | +30.7% | Oct 12, 2026 |
| Goldman Sachs | Analyst unavailable | $87 | $72.99 | +27.8% | Oct 8, 2026 |
| Oppenheimer | Analyst unavailable | $82 | $73.33 | +20.4% | Oct 6, 2026 |
| Vertical Research | Analyst unavailable | $74 | $67.26 | +8.7% | Oct 5, 2026 |
| Mizuho Securities | Analyst unavailable | $84 | $67.26 | +23.4% | Oct 5, 2026 |
| Morgan Stanley | Analyst unavailable | $85 | $68.26 | +24.8% | Oct 2, 2026 |
| BMO Capital | Joel Jackson | $85 | $68.26 | +24.8% | Oct 2, 2026 |
| RBC Capital | Arun Viswanathan | $85 | $68.26 | +24.8% | Oct 2, 2026 |
Track every rating change on VYLR the moment it posts. Free to start.
Start freeVylor is an advanced seed and genetics company focused on delivering groundbreaking innovation to farmers. Anchored in elite germplasm and transformative biotechnology, the company leverages its scientific expertise to develop next-generation technology to help farmers around the world boost yields.
| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| SQM Sociedad Química y Minera de Chile S.A. | FY2026 Q3 · Calendar Q4 2026 | -3.0% | -5.5% | SQM Sees Lithium Demand Growth but Flags Price and Inventory Risks |
| CTA-PA EIDP, Inc. | FY2026 Q3 · Calendar Q3 2026 | +232.7% | — | New-product growth cushions EIDP, but Brazil weakness drives a lower outlook |
| CTA-PB EIDP, Inc. USD 4.50 Cum Pfd Registered Shs | FY2026 Q3 · Calendar Q3 2026 | — | — | New-product growth held up, but Brazil weakness cut the EBITDA outlook |
| CTVA Corteva, Inc. | FY2026 Q3 · Calendar Q4 2026 | +231.9% | -19.6% | Corteva Q3: New Products Grow as Brazil Weakness Cuts Outlook |
| FNV Franco-Nevada Corporation | FY2026 Q3 · Calendar Q4 2026 | +6.8% | -2.4% | Franco-Nevada Q3: stronger earnings, but revenue missed estimates |
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-12. For educational purposes only; not investment advice.